TPG-Axon Capital pays CV Therapeutics $185M for contrast agent rights
TPG-Axon Capital, a New York City-based investment firm, has agreed to pay CV Therapeutics up to $185 million in exchange for rights to 50 percent of CV Therapeutics’ royalty on North American sales of Lexiscan (regadenoson) injection.
CV Therapeutics said it received $175 million on closing of the transaction and could receive a potential future milestone payment of $10 million.
On April 10, the FDA approved Lexiscan (regadenoson) injection, an A2A adenosine receptor agonist, for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging in patients unable to undergo adequate exercise stress.
CV Therapeutics of Palo Alto, Calif., said it retains rights to the other 50 percent of royalty revenue from North American sales of the product, and also may receive a royalty on another Astellas product under the terms of the company's collaboration agreement with the Deerfield, Ill.-based Astellas Pharma US.
“With the funds from this non-dilutive financing and multiple product-related revenue streams, we believe CV Therapeutics now has the funds to become cash flow positive and meet the debt obligation which is putable in 2010, both without requiring capital market financing or partnership dollars,” said Louis G. Lange, MD, PhD, chairman and CEO of CV Therapeutics. “We are aggressively pursuing a partner to support Ranexa commercialization and this additional financial independence provides important leverage for managing both the balance sheet and our discussions with potential partners.”
CV Therapeutics said it owns the rights for regadenoson outside of North America and expects to submit a marketing authorization application for the product to the European Medicines Agency by the end of 2008.
CV Therapeutics said it received $175 million on closing of the transaction and could receive a potential future milestone payment of $10 million.
On April 10, the FDA approved Lexiscan (regadenoson) injection, an A2A adenosine receptor agonist, for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging in patients unable to undergo adequate exercise stress.
CV Therapeutics of Palo Alto, Calif., said it retains rights to the other 50 percent of royalty revenue from North American sales of the product, and also may receive a royalty on another Astellas product under the terms of the company's collaboration agreement with the Deerfield, Ill.-based Astellas Pharma US.
“With the funds from this non-dilutive financing and multiple product-related revenue streams, we believe CV Therapeutics now has the funds to become cash flow positive and meet the debt obligation which is putable in 2010, both without requiring capital market financing or partnership dollars,” said Louis G. Lange, MD, PhD, chairman and CEO of CV Therapeutics. “We are aggressively pursuing a partner to support Ranexa commercialization and this additional financial independence provides important leverage for managing both the balance sheet and our discussions with potential partners.”
CV Therapeutics said it owns the rights for regadenoson outside of North America and expects to submit a marketing authorization application for the product to the European Medicines Agency by the end of 2008.